

(51) International Patent Classification:
C07K 16/28 (2006.01)(21) International Application Number:
PCT/US2021/031605(22) International Filing Date:
10 May 2021 (10.05.2021)

(25) Filing Language: English

(26) Publication Language: English


(30) Priority Data:
63/022,309 08 May 2020 (08.05.2020) US(71) Applicant: **ELECTRA THERAPEUTICS, INC.**
[US/US]; 681 Gateway Boulevard, 3rd Floor, South San Francisco, CA 94080 (US).(72) Inventors: **PANICKER, Sandip**; c/o Electra Therapeutics, Inc., 681 Gateway Boulevard, 3rd Floor, South San Francisco, CA 94080 (US). **ROSENTHAL, Adam, David**; c/o Electra Therapeutics, Inc., 681 Gateway Boulevard,3rd Floor, South San Francisco, CA 94080 (US). **ROSE, Eileen, Lingshu**; c/o Electra Therapeutics, Inc., 681 Gateway Boulevard, 3rd Floor, South San Francisco, CA 94080 (US).(74) Agent: **ROY, Madhuri** et al.; Cooley LLP, 1299 Pennsylvania Ave., Suite 700, Washington, DC 20004 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

(54) Title: SIRP ALPHA, SIRP BETA 1, AND SIRP GAMMA ANTIBODIES AND USES THEREOF

FIG. 1B



(57) **Abstract:** Provided herein are antibodies that bind signal regulatory protein gamma (SIRP γ), as well as SIRP α and/or SIRP β 1, and methods of using such antibodies (referred to as SIRP antibodies). In some embodiments, the SIRP antibodies are human monoclonal antibodies that bind human SIRP γ as well as SIRP α and/or SIRP β 1. In some embodiments, the SIRP antibodies provided herein are useful for treating a disease or condition associated with overactivation and/or hyperproliferation of lymphocytes, myeloid cells, or a combination thereof, or a disease or condition associated with SIRP α , SIRP β 1 and/or SIRP γ activity.

[Continued on next page]

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))